Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin and TACE for Early-stage HCC With ASPH Overexpression
NCT02724332Phase 1Completed
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Nov 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sirolimus in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Overall Survival at 3 years. Started Nov 2012; status: completed.
02
Drugs
sirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02724332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724332.